脂蛋白磷脂酶A2在2型糖尿病及其大血管病变中的作用被引量：2

The value of lipoprotein-associated phospholipase A2 in type 2 diabetes mellitus and the macrovascular complications

下载PDF

导出

摘要目的探究脂蛋白磷脂酶A2在2型糖尿病大血管病变中的作用。方法选择26例2型糖尿病合并颈动脉粥样斑块患者和24例单纯2型糖尿病患者,分别测定脂蛋白磷脂酶A2水平,并对结果进行组间比较。结果 2型糖尿病合并颈动脉粥样斑块组脂蛋白磷脂酶A2水平高于单纯2型糖尿病患者,且低密度脂蛋白、糖化血红蛋白、颈动脉内中膜厚度水平均高于单纯2型糖尿病患者,组间比较差异存在统计学意义(P<0.05)。结论脂蛋白磷脂酶A2对2型糖尿病患者早期大血管病变有预测作用,为糖尿病大血管病变的早期干预提供了帮助。 Objective To investigate the relation between the level of lipoprotein-associated phospholipase A2 （Lp- PLA2） with type 2 diabetes mellitus and its vascular complications. Methods Collected the clinical data of 26 patients with type 2 diabetes mellitus complicated with carotid atherosclerotic plaque and 24 cases of type 2 diabetes mellitus without vascu- lopathy .The lipoprotein-associated phospholipase A2 levels were measured respectively, and carried on the comparison between two groups. Results The lipoprotein-associated phospholipase A2 level was significantly higher in patients with type 2 dia- betes mellitus complicated with carotid atherosclerotic plaque than that in patients with type 2 diabetes mellitus without macrovasculopathy. Meanwhile, the levels of low density lipoprotein cholesterol （HDL-c）, glycosylated hemoglobin and carotid intima-media thickness in patients with type 2 diabetes mellitus complicated with carotid atherosclerotic plaque were also higher than that in patients with type 2 diabetes mellitus without macrovasculopathy. There was significant difference between two groups （P〈0.05）. Conclusion The lipoprotein-associated phospholipase A2 has the predictional significance for early maerovasculopathy in type 2 diabetes mellitus, and is helpful for early intervene of diabetic macrovaseulopathy in type 2 diabetes mellitus.

作者苏敏薛莉

机构地区江苏省南通市中医院内分泌科

出处《中国现代医药杂志》 2015年第10期55-57,共3页 Modern Medicine Journal of China

关键词脂蛋白磷脂酶A2 2型糖尿病大血管病变 Lipoprotein-associated phospholipase A2（Lp-PLA2） Type 2 diabetes mellitus Maerovasculopathy

分类号 R587.2 [医药卫生—内分泌]

引文网络
相关文献

参考文献7

1Guang Ning and Reaction Study Group.Risk Evaluation of cAn- cers in Chinese diabe Tic Individuals:A lONgitudinal (REAC- TION)study. J Diabetes,2012,4:172-173.
2Sigurdardottir V, Fagerberg B, Hulthe J. Preclinical atherosclerosis and inflammation in 61-year-old men with newly diagnosed dia- betes and established diabetes [J]. Diabetes Care,2004,27 (4) : 880-884.
3Lavi S,Herrmann J,Lavi R,et al. Role of lipoprotein-associated phospholipase A2 in atherosclerosis [J]. Curr Atheroscler Rep, 2008,10(3) :230-235.
4Libby P,Ridker PM, Maseri A. Inflammation and atheroselerosis [J].Cireulation, 2002,105 : 1135-1143.
5Koenig W,Twardella D,Brenner H,et al. Lipoprotein- associ- ated phospholipase A2 predicts future cardiovascular events in patients with coronary heart, disease independently of traditional risk factors,markers of inflammation,renal function,and hemo- dynamic stress [J]. Arterioscler Thromb Vasc Biol, 2006,26 (7) : 1586-1593.
6Kolodgie FD,Burke AP,Skorija KS,et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis[J].Arterioscler Thromb Vasc Biol, 2006,26 : 2523-2529.
7曾繁芳,蔡安平,刘幼文,金光临,王涓,潘楚梅.血浆脂蛋白相关性磷脂酶A2活性与颈动脉内中膜厚度的关系[J].岭南心血管病杂志,2013,19(1):77-79. 被引量：2

二级参考文献11

1KINNEY G L, SNELL-BERGEON J K, MAAHS D M,et al.Lipoprotein-associated phospholipase A activity predictsprogression of subclinical coronary atherosclerosis [J]. DiabetesTechnol Ther, 2011,13(3): 381-387.
2TSELEPIS A F, RIZZO M, GOUDEVENOS i A. Therapeuticmodulation of lipoprotein-associated phospholipase A2 (Lp-PLA2)[J]. Curr Pharm Des, 2011, 17(33): 3656-3661.
3IKONOMIDIS I,MICHALAKEAS C A, LEKAKIS J, et al.The role of lipoprotein-associated phospholipase A2 (Lp-PLA)in cardiovascular disease [J]. Rev Recent Clin Trials, 2011, 6(2): 108-113.
4GONG H P, DU Y M, ZHONG L N, et al. Plasma lipoprotein-associated phospholipase A2 in patients with metabolicsyndrome and carotid atherosclerosis[J]. Lipids Health Dis, 2011,10(1): 13.
5KAKKOS S K, TSOLAKIS I A. The emerging role oflipoprotein-associated phospholipase A2 in cerebrovasculardisease[J]. Eur J Vase Endovasc Surg, 2012. 43(2) ; 160.
6VITTOS O, TO ANA B t VITTOS A, et al. Lipoprotein-associated phospholipase A2 (Lp-PLA2) : a review of its roleand significance as a cardiovascular biomarker [ J ]. Biomarkers,2012,17(4): 289-302.
7SANCHEZ-QUESADA J L,VINAGRE I,JUAN-FRANCO E D,et al. Effect of improving glycemic control in patients with type2 diabetes mellitus on low-density lipoprotein size,electronegative low-density lipoprotein and lipoprotein-associated phospholipase A2 distribution [J]. Am J Cardiol, 2012,110(1): 67-71.
8GUO Z G, LI C , ZHONG J K, et al. Laboratory investigationof dysfunctional HDL[J]. Chem Phys Lipids,2012,165( 1 ):32-37.
9KLEBER M E,WOLFERT R L, DE MOISSL G D, et al.Lipoprotein associated phospholipase A2 concentration predictstotal and cardiovascular mortality independently of establishedrisk factors (The Ludwigshafen Risk and Cardiovascular HealthStudy) [J]. Clin Lab, 2011,57(9-10): 659-667.
10PAIK J K, KIM J Y, KIM O Y,et al. Circulating and PBMCLp-PLA2 associate differently with oxidative stress andsubclinical inflammation in nonobese women (menopausalstatus) [ J]. Plos One, 2012,7(2) : e296-e275.